{
  "1XT.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Xintela AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "XINTELA AB",
    "state": null,
    "summary": "Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing Xintela Assay for Cell Therapy (XACT), an analytical test for cell therapy. It also offers XSTEM-OA, a stem cell-based product for the treatment of osteoarthritis in humans. In addition, the company develops stem cell-based products for animals. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.",
    "website": "http://www.xintela.se",
    "zipcode": "223 81"
  },
  "1YG.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Immunicum AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMMUNICUM AB",
    "state": null,
    "summary": "Immunicum AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II clinical trial for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as has completed Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I ALISON clinical trial for the treatment of ovarian cancers. It has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase Ib/II study; and research collaboration with Icahn School of Medicine At Mount Sinai. The company is headquartered in Stockholm, Sweden.",
    "website": "http://immunicum.se",
    "zipcode": "114 42"
  },
  "2E9.F": {
    "city": "HÃ¤gersten",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Intervacc AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "INTERVACC AB",
    "state": null,
    "summary": "Intervacc AB (publ), a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. It offers vaccines, pharmaceuticals, and vitamins for horses, piglets, and cows. The company also provides veterinary bacteriological and mycological analyses for veterinarians and animal hospitals. It serves customers in Nordic countries and the Baltic states. Intervacc AB (publ) holds an agreement with the Swedish University of Agricultural Sciences, SLU for the development of animal health vaccines. The company is based in HÃ¤gersten, Sweden.",
    "website": "http://www.intervacc.se",
    "zipcode": "129 44"
  },
  "2I9.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Karolinska Development AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KAROLINSKA DEVELOP.AB",
    "state": null,
    "summary": "Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.karolinskadevelopment.com",
    "zipcode": "17165"
  },
  "3EE0.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Kancera AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KANCERA AB",
    "state": null,
    "summary": "Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567 and KAND145 which block the Fractalkine receptor CX3CR1 and thus specific parts of the immune system for treatment of hyperinflammation HDAC6 for the treatment of nerve inflammation and pain; and ROR inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.",
    "website": "http://www.kancera.com",
    "zipcode": "171 65"
  },
  "4CX.F": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Cyxone AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CYXONE AB  SK-,75",
    "state": null,
    "summary": "Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis; and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and T20K that would enter clinical Phase I for multiple sclerosis. The company was founded in 2015 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.cyxone.com",
    "zipcode": "221 22"
  },
  "4K4.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Stayble Therapeutics AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "STAYBLE THERAPEUTICS AB",
    "state": null,
    "summary": "Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) is based in Gothenburg, Sweden.",
    "website": "http://www.staybletherapeutics.se",
    "zipcode": "413 90"
  },
  "4SA.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "AcouSort AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACOUSORT AB O.N.",
    "state": null,
    "summary": "AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.",
    "website": "http://www.acousort.com",
    "zipcode": "223 81"
  },
  "52X.F": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Magle Chemoswed Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MAGLE CHEMOSWED HOLDING",
    "state": null,
    "summary": "Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacture of pharmaceutical products and technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); research, development, and production of products in the areas of wound care and diagnostics, with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical device technology products in the areas of advanced wound care, surgical and diagnostics, drug delivery, which include its marketed technology products comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; and SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company is headquartered in MalmÃ¶, Sweden. Magle Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.",
    "website": "http://www.maglechemoswed.cow",
    "zipcode": "212 15"
  },
  "5GV.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Genovis AB (publ.)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "GENOVIS AB  SE-,40",
    "state": null,
    "summary": "Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.",
    "website": "http://www.genovis.com",
    "zipcode": "220 07"
  },
  "5IU.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Isofol Medical AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ISOFOL MEDICAL AB",
    "state": null,
    "summary": "Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, Solasia Pharma KK, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.",
    "website": "http://isofolmedical.com",
    "zipcode": "413 46"
  },
  "5J9.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Fluicell AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "FLUICELL AB",
    "state": null,
    "summary": "Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.",
    "website": "http://www.fluicell.com",
    "zipcode": "413 46"
  },
  "5JA1.F": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Sprint Bioscience AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SPRINT BIOSCIENCE AB",
    "state": null,
    "summary": "Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PIP4K2, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.",
    "website": "http://www.sprintbioscience.com",
    "zipcode": "141 57"
  },
  "5JK.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "ISR Immune System Regulation Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ISR IMMUNE SYS.REGUL.HLDG",
    "state": null,
    "summary": "ISR Immune System Regulation Holding AB (publ) researches and develops drugs for the treatment of viral infections in Sweden. The company's product candidates include ISR048 that has completed Phase I/IIa clinical trial for the treatment of human immunodeficiency virus infection (HIV); and ISR049, which is in the development stage to treat HIV. It is also developing a second line of chemical entities, including ISR050 that has immunostimulatory properties. The company is headquartered in Stockholm, Sweden.",
    "website": "http://israb.se",
    "zipcode": "113 40"
  },
  "5LU.F": {
    "city": "HammenhÃ¶g",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Simris Alg AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SIMRIS ALG AB  B",
    "state": null,
    "summary": "Simris Alg AB (publ) manufactures and sells dietary supplements and algae-based foods in Sweden and internationally. It offers Simris Algae Omega-3, a plant-based marine omega-3 EPA and DHA line; and a line of algae-based products, such as finest chlorella, spirulina sprinkles, boosting astaxanthin, flower power algae tea, and sun candy algae tea under the Simris Select brand. The company was founded in 2010 and is headquartered in HammenhÃ¶g, Sweden.",
    "website": "http://www.simrisalg.se",
    "zipcode": "276 50"
  },
  "65G.F": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "NextCell Pharma AB",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NEXTCELL PHARMA AB",
    "state": null,
    "summary": "NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases, as well as for use in kidney transplants. It also provides a service under the Cellaviva brand name, which is a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. The company has a partnership with Bonzun Health Information AB. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden.",
    "website": "http://www.nextcellpharma.com",
    "zipcode": "141 57"
  },
  "6XP.SG": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Xspray Pharma AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "XSpray Pharma AB Namn-Aktier o.",
    "state": null,
    "summary": "Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.",
    "website": "http://www.xspraypharma.com",
    "zipcode": "169 67"
  },
  "6Y4.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Vicore Pharma Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "VICORE PHARMA HOLDING AB",
    "state": null,
    "summary": "Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), diffuse systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.vicorepharma.com",
    "zipcode": "411 05"
  },
  "78D.F": {
    "city": "MÃ¶lndal",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Alzinova AB",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALZINOVA AB",
    "state": null,
    "summary": "Alzinova AB, a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic AÃ oligomers. The company was founded in 2011 and is based in MÃ¶lndal, Sweden.",
    "website": "http://www.alzinova.com",
    "zipcode": "431 83"
  },
  "7AL.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Alligator Bioscience AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ALLIGATOR BIOSC. AB O.N.",
    "state": null,
    "summary": "Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in the United States, Sweden, Asia, and internationally. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial to treat metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
    "website": "http://www.alligatorbioscience.se",
    "zipcode": "223 81"
  },
  "7CA.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Camurus AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CAMURUS AB",
    "state": null,
    "summary": "Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; and episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity. Its products pipeline also includes Brixadi for opioid dependence; CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension and Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which has completed Phase I clinical trials for the treatment of Endocrine disorder; CAM4083 for treatment of myasthenia gravis and other serious tissue-based complement-mediated disorders; CAM2047 for the treatment of chemotherapy induced nausea and vomiting; and CAM2048 for postoperative pain. The company was founded in 1991 and is headquartered in Lund, Sweden.",
    "website": "http://www.camurus.com",
    "zipcode": "223 70"
  },
  "7IZ.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Ziccum AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ZICCUM AB",
    "state": null,
    "summary": "Ziccum AB (publ) develops dry powder preparations of biological pharmaceuticals. The company develops and commercializes LaminarPace, a spray drying technology that dries chemicals, vaccines, biologics, and drug substances at room temperature. Its dry powder biologics includes proteins, antibodies, vaccine viruses, and other products. The company was founded in 2017 and is headquartered in Lund, Sweden.",
    "website": "http://www.ziccum.com",
    "zipcode": "223 70"
  },
  "7UX.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Spago Nanomedical AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SPAGO NANOMEDICAL AB",
    "state": null,
    "summary": "Spago Nanomedical AB (publ) develops nanomaterials for cancer diagnostics and treatment. It offers SpagoPix, a cancer selective MRI contrast agent; and Tumorad, a tumor selective radiation treatment. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was founded in 2007 and is based in Lund, Sweden.",
    "website": "http://spagonanomedical.se",
    "zipcode": "223 63"
  },
  "7V3.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Cantargia AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CANTARGIA AB",
    "state": null,
    "summary": "Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It is also developing CANxx antibodies against IL1RAP that have other properties than CAN04 and CAN10. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.",
    "website": "http://cantargia.com",
    "zipcode": "223 63"
  },
  "7Z60.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Coegin Pharma AS",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "COEGIN PHARMA AB",
    "state": null,
    "summary": "Coegin Pharma AS, a clinical-stage pharmaceutical company, engages in the discovery and development of novel small molecule therapeutics for the treatment of serious medical conditions associated with chronic inflammatory disorders and specific cancers. Its lead compound AVX001 is a therapy for the treatment of psoriasis and other skin conditions. The company's other products include AVX002 for the treatment of chronic kidney disease (glomerulonephritis); AVX235 for the treatment of triple-negative breast cancer; and AVX420 for the treatment of cancer. Coegin Pharma AS was founded in 2005 and is based in Lund, Sweden. Coegin Pharma AS operates as a subsidiary of Coegin Pharma AB.",
    "website": "http://coeginpharma.com",
    "zipcode": "223 81"
  },
  "8LY.F": {
    "city": "Bromma",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "OncoZenge AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ONCOZENGE AB",
    "state": null,
    "summary": "OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).",
    "website": "http://www.oncozenge.se",
    "zipcode": "167 51"
  },
  "8T0.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Promore Pharma AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PROMORE PHARMA AK",
    "state": null,
    "summary": "Promore Pharma AB (publ), a biopharmaceutical company, develops therapeutic peptides for the bio-active wound care market in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand, which is in Phase III trial; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers and for the treatment of diabetic foot ulcers. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is based in Solna, Sweden.",
    "website": "http://www.promorepharma.com",
    "zipcode": "171 65"
  },
  "8V6.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Scandinavian ChemoTech AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SCANDINAV.CHEMOTECH CL.B",
    "state": null,
    "summary": "Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.",
    "website": "http://chemotech.se",
    "zipcode": "223 63"
  },
  "8X4.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Eurocine Vaccines AB (publ)",
    "market": "dr_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "EUROCINE VACCINES NAM.",
    "state": null,
    "summary": "Eurocine Vaccines AB (publ) develops vaccines in Sweden. It has a research and collaboration agreement with Spixia Biotechnology AB to develop, manufacture, and commercialize chlamydia vaccine candidates. The company is based in Solna, Sweden.",
    "website": "http://www.eurocine-vaccines.com",
    "zipcode": "171 65"
  },
  "958.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Pharmiva AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMIVA AB",
    "state": null,
    "summary": "Pharmiva AB (publ) engages in the research and development of medical products. The company develops Vernivia, an over-the-counter vaginal mousse for the treatment of bacterial vaginosis. The company is based in Lund, Sweden.",
    "website": "http://www.pharmiva.com",
    "zipcode": "22270"
  },
  "99B.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "QuiaPEG Pharmaceuticals Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "QUIAPEG PHARMAC.H.SK-1,20",
    "state": null,
    "summary": "QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.",
    "website": "http://www.quiapeg.com",
    "zipcode": "171 65"
  },
  "9IB.SG": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Infant Bacterial Therapeutics AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Infant Bacterial Therapeutics N",
    "state": null,
    "summary": "Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.",
    "website": "http://www.ibtherapeutics.com",
    "zipcode": "111 21"
  },
  "9II.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Biovica International AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOVICA INTERNATIONAL",
    "state": null,
    "summary": "Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome in Europe, the United States, and Asia. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves pharmaceutical companies and contract research organizations. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.biovica.com",
    "zipcode": "752 37"
  },
  "9RP.F": {
    "city": "UmeÃ¥",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Lipigon Pharmaceuticals AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIPIGON PHARMA. AB",
    "state": null,
    "summary": "Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) was founded in 2010 and is based in UmeÃ¥, Sweden.",
    "website": "http://www.lipigon.se",
    "zipcode": "90736"
  },
  "A6X.F": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "aXichem AB",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "AXICHEM AB A",
    "state": null,
    "summary": "aXichem AB develops, patents, and markets natural-analogue industrial compounds for the marine, pest control, feed ingredient, and medical application markets in Sweden and internationally. It offers aXiphen-repellent, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; aXiphen-feed ingredient for pig and poultry diets; and aXiphen for use in various foods and dietary supplements, as well as in the pharmaceutical industry. The company is based in MalmÃ¶, Sweden.",
    "website": "http://www.axichem.com",
    "zipcode": "211 34"
  },
  "ACE.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Ascelia Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Ascelia Pharma AB",
    "state": null,
    "summary": "Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. The company was founded in 2000 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.ascelia.com",
    "zipcode": "215 32"
  },
  "ACOU.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "AcouSort AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AcouSort AB",
    "state": null,
    "summary": "AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.",
    "website": "http://www.acousort.com",
    "zipcode": "223 81"
  },
  "ACTI.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Active Biotech AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Active Biotech AB",
    "state": null,
    "summary": "Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. The company is developing Naptumomab, an anti-cancer immunotherapy that is in Phase Ib/II clinical trial to treat patients with advanced solid tumors; and Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial for the treatment of relapsed or refractory multiple myeloma. It is also developing Laquinimod, a small molecule immuno-modulator to treat inflammatory eye disorders, non-infectious uveitis, and wet age-related macular degeneration (wAMD). The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden.",
    "website": "http://www.activebiotech.com",
    "zipcode": "223 63"
  },
  "ALZ.ST": {
    "city": "MÃ¶lndal",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Alzinova AB",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Alzinova AB",
    "state": null,
    "summary": "Alzinova AB, a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic AÃ oligomers. The company was founded in 2011 and is based in MÃ¶lndal, Sweden.",
    "website": "http://www.alzinova.com",
    "zipcode": "431 83"
  },
  "ANNX.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Annexin Pharmaceuticals AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Annexin Pharmaceuticals AB",
    "state": null,
    "summary": "Annexin Pharmaceuticals AB (publ), a biotechnology company, engages in developing drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.",
    "website": "http://www.annexinpharma.com/sv",
    "zipcode": "113 29"
  },
  "ASAP.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Asarina Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Asarina Pharma AB",
    "state": null,
    "summary": "Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder, as well as in Phase IIa clinical trial for the treatment of menstrual migraine and Tourette syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.",
    "website": "http://www.asarinapharma.com",
    "zipcode": "171 65"
  },
  "ATORX.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Alligator Bioscience AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Alligator Bioscience AB",
    "state": null,
    "summary": "Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in the United States, Sweden, Asia, and internationally. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial to treat metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
    "website": "http://www.alligatorbioscience.se",
    "zipcode": "223 81"
  },
  "AXIC-A.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "aXichem AB",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "aXichem AB ser. A",
    "state": null,
    "summary": "aXichem AB develops, patents, and markets natural-analogue industrial compounds for the marine, pest control, feed ingredient, and medical application markets in Sweden and internationally. It offers aXiphen-repellent, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; aXiphen-feed ingredient for pig and poultry diets; and aXiphen for use in various foods and dietary supplements, as well as in the pharmaceutical industry. The company is based in MalmÃ¶, Sweden.",
    "website": "http://www.axichem.com",
    "zipcode": "211 34"
  },
  "B9A.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "BioArctic AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOARCTIC AB B",
    "state": null,
    "summary": "BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops BAN0805, an anti-alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.",
    "website": "http://www.bioarctic.se",
    "zipcode": "112 51"
  },
  "BINV.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "BioInvent International AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BioInvent International AB",
    "state": null,
    "summary": "BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, rest of Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia. The company is also developing cancer-associated regulatory T cells which modulate the immune system; and BI-1808 and BI-1910, an anti-TNFR2 antibody for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL). It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors; and a collaboration agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was incorporated in 1996 and is headquartered in Lund, Sweden.",
    "website": "http://www.bioinvent.com",
    "zipcode": "223 70"
  },
  "BIOA-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "BioArctic AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BioArctic AB ser. B",
    "state": null,
    "summary": "BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops BAN0805, an anti-alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.",
    "website": "http://www.bioarctic.se",
    "zipcode": "112 51"
  },
  "BIOVIC-B.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Biovica International AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Biovica International AB ser. B",
    "state": null,
    "summary": "Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome in Europe, the United States, and Asia. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves pharmaceutical companies and contract research organizations. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.biovica.com",
    "zipcode": "752 37"
  },
  "BIOWKS.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Bio-Works Technologies AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Bio-Works Technologies AB",
    "state": null,
    "summary": "Bio-Works Technologies AB (publ) researches, develops, manufactures, and supplies agarose based resins used to separate proteins and other biomolecules. It offers activated and affinity resins; BabyBio columns; immobilized metal-ion affinity chromatography (IMAC) resins; ion exchange resins; OptioBio glass columns; and size exclusion chromatography (SEC) resins. The company's products are used in antibody, His-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines purification process. Bio-Works Technologies AB (publ) founded in 2006 and is based in Uppsala, Sweden.",
    "website": "http://www.bio-works.com",
    "zipcode": "75450"
  },
  "BIX0.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "BioInvent International AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOINVENT INTERN.  SK 2",
    "state": null,
    "summary": "BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, rest of Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia. The company is also developing cancer-associated regulatory T cells which modulate the immune system; and BI-1808 and BI-1910, an anti-TNFR2 antibody for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL). It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors; and a collaboration agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was incorporated in 1996 and is headquartered in Lund, Sweden.",
    "website": "http://www.bioinvent.com",
    "zipcode": "223 70"
  },
  "BTPC.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Active Biotech AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACTIVE BIOTECH  SK 10",
    "state": null,
    "summary": "Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. The company is developing Naptumomab, an anti-cancer immunotherapy that is in Phase Ib/II clinical trial to treat patients with advanced solid tumors; and Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial for the treatment of relapsed or refractory multiple myeloma. It is also developing Laquinimod, a small molecule immuno-modulator to treat inflammatory eye disorders, non-infectious uveitis, and wet age-related macular degeneration (wAMD). The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden.",
    "website": "http://www.activebiotech.com",
    "zipcode": "223 63"
  },
  "CAMX.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Camurus AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Camurus AB",
    "state": null,
    "summary": "Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; and episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity. Its products pipeline also includes Brixadi for opioid dependence; CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension and Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which has completed Phase I clinical trials for the treatment of Endocrine disorder; CAM4083 for treatment of myasthenia gravis and other serious tissue-based complement-mediated disorders; CAM2047 for the treatment of chemotherapy induced nausea and vomiting; and CAM2048 for postoperative pain. The company was founded in 1991 and is headquartered in Lund, Sweden.",
    "website": "http://www.camurus.com",
    "zipcode": "223 70"
  },
  "CANTA.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Cantargia AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Cantargia AB",
    "state": null,
    "summary": "Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It is also developing CANxx antibodies against IL1RAP that have other properties than CAN04 and CAN10. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.",
    "website": "http://cantargia.com",
    "zipcode": "223 63"
  },
  "CLBIO.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Corline Biomedical AB",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Corline Biomedical AB",
    "state": null,
    "summary": "Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.",
    "website": "http://www.corline.se",
    "zipcode": "754 50"
  },
  "CMOTEC-B.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Scandinavian ChemoTech AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Scandinavian ChemoTech AB B",
    "state": null,
    "summary": "Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.",
    "website": "http://chemotech.se",
    "zipcode": "223 63"
  },
  "COMBI.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "CombiGene AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Combigene AB",
    "state": null,
    "summary": "CombiGene AB (publ) engages in the development and commercialization of gene therapy for the treatment of neurological and psychiatric disorders. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy. CombiGene AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.",
    "website": "http://www.combigene.com",
    "zipcode": "223 81"
  },
  "CYXO.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Cyxone AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Cyxone AB",
    "state": null,
    "summary": "Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis; and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and T20K that would enter clinical Phase I for multiple sclerosis. The company was founded in 2015 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.cyxone.com",
    "zipcode": "221 22"
  },
  "DMN.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Diamyd Medical AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "DIAMYD MEDICAL B",
    "state": null,
    "summary": "Diamyd Medical AB (publ) engages in developing therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunomodulating diabetes vaccine for the treatment of type 1 diabetes and latent autoimmune diabetes, which is in Phase IIb clinical development; and Remygen, an oral regenerative and immunomodulatory drug candidate for the treatment of autoimmune and type 2 diabetes, which is in Phase I/II clinical development. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is based in Stockholm, Sweden.",
    "website": "http://www.diamyd.com",
    "zipcode": "111 56"
  },
  "DMYD-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Diamyd Medical AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Diamyd Medical AB ser. B",
    "state": null,
    "summary": "Diamyd Medical AB (publ) engages in developing therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunomodulating diabetes vaccine for the treatment of type 1 diabetes and latent autoimmune diabetes, which is in Phase IIb clinical development; and Remygen, an oral regenerative and immunomodulatory drug candidate for the treatment of autoimmune and type 2 diabetes, which is in Phase I/II clinical development. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is based in Stockholm, Sweden.",
    "website": "http://www.diamyd.com",
    "zipcode": "111 56"
  },
  "EGTX.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Egetis Therapeutics AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Egetis Therapeutics AB",
    "state": null,
    "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was founded in 2006 and is based in Stockholm, Sweden.",
    "website": "http://www.egetis.com",
    "zipcode": "114 46"
  },
  "FLUI.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Fluicell AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Fluicell AB",
    "state": null,
    "summary": "Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.",
    "website": "http://www.fluicell.com",
    "zipcode": "413 46"
  },
  "GENO.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Genovis AB (publ.)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Genovis AB",
    "state": null,
    "summary": "Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.",
    "website": "http://www.genovis.com",
    "zipcode": "220 07"
  },
  "GUARD.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Guard Therapeutics International AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Guard Therapeutics Internationa",
    "state": null,
    "summary": "Guard Therapeutics International AB (publ) develops and commercializes medical applications for the diagnosis and treatment of pre-eclampsia and kidney damage in Sweden. It offers ROSGard, a drug candidate that is based on alpha-1-microglobulin protein, which protects and repairs damaged kidney tissues. The company has collaboration with Antaros Medical to conduct a study in humans undergoing radiation therapy of neuroendocrine tumors. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) is based in Lund, Sweden.",
    "website": "http://www.guardtherapeutics.com",
    "zipcode": "223 63"
  },
  "HNSA.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Hansa Biopharma AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Hansa Biopharma AB",
    "state": null,
    "summary": "Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), an antibody cleaving enzyme that is in Phase II for enabling kidney transplantations in sensitized patients, as well as for anti-GBM antibody disease and Guillain BarrÃ© syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.",
    "website": "http://www.hansabiopharma.com",
    "zipcode": "222 63"
  },
  "IBT-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Infant Bacterial Therapeutics AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Infant Bacterial Therapeutics A",
    "state": null,
    "summary": "Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.",
    "website": "http://www.ibtherapeutics.com",
    "zipcode": "111 21"
  },
  "IDOGEN.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Idogen AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Idogen AB",
    "state": null,
    "summary": "Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, or the body's own cells or tissues in Sweden. Its advanced product candidate is IDO 8, designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII. The company also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection, primarily kidney transplant rejection; and IDO AID for severe and rare autoimmune diseases. The company was founded in 2008 and is headquartered in Lund, Sweden.",
    "website": "http://www.idogen.com",
    "zipcode": "223 81"
  },
  "IMMU.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Immunicum AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Immunicum AB",
    "state": null,
    "summary": "Immunicum AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II clinical trial for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as has completed Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I ALISON clinical trial for the treatment of ovarian cancers. It has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase Ib/II study; and research collaboration with Icahn School of Medicine At Mount Sinai. The company is headquartered in Stockholm, Sweden.",
    "website": "http://immunicum.se",
    "zipcode": "114 42"
  },
  "INDEX.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "InDex Pharmaceuticals Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "InDex Pharmaceuticals Holding A",
    "state": null,
    "summary": "InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in late stage clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in discovery stage for use in the treatment of various immunological diseases. InDex Pharmaceuticals Holding AB (publ) was founded in 2015 and is headquartered in Solna, Sweden.",
    "website": "http://www.indexpharma.com",
    "zipcode": "171 65"
  },
  "IRLAB-A.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "IRLAB Therapeutics AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IRLAB Therapeutics AB ser. A",
    "state": null,
    "summary": "IRLAB Therapeutics AB (publ), a research and development company, develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; Pirepemat, which is in phase II clinical trial for the treatment of Postural dysfunction. It also develops IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing. In addition, the company develops P003, a research project that develops drugs as a substitute of levodopa for Parkinson's disease. The company is based in Gothenburg, Sweden.",
    "website": "http://www.irlab.se",
    "zipcode": "413 46"
  },
  "ISOFOL.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Isofol Medical AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Isofol Medical AB",
    "state": null,
    "summary": "Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, Solasia Pharma KK, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.",
    "website": "http://isofolmedical.com",
    "zipcode": "413 46"
  },
  "ISR.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "ISR Immune System Regulation Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ISR Immune System Regulation Ho",
    "state": null,
    "summary": "ISR Immune System Regulation Holding AB (publ) researches and develops drugs for the treatment of viral infections in Sweden. The company's product candidates include ISR048 that has completed Phase I/IIa clinical trial for the treatment of human immunodeficiency virus infection (HIV); and ISR049, which is in the development stage to treat HIV. It is also developing a second line of chemical entities, including ISR050 that has immunostimulatory properties. The company is headquartered in Stockholm, Sweden.",
    "website": "http://israb.se",
    "zipcode": "113 40"
  },
  "ITECH.ST": {
    "city": "MÃ¶lndal",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "I-Tech AB",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "I-Tech AB",
    "state": null,
    "summary": "I-Tech AB, a bio-technology company, develops and commercializes fouling prevention products in Sweden. The company offers Selektope, a bio-repellent ingredient for marine coatings that provide hard fouling prevention for ships. It serves marine coatings manufacturers. The company was founded in 2000 and is based in MÃ¶lndal, Sweden.",
    "website": "http://www.i-tech.se",
    "zipcode": "431 83"
  },
  "IVACC.ST": {
    "city": "HÃ¤gersten",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Intervacc AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Intervacc AB",
    "state": null,
    "summary": "Intervacc AB (publ), a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. It offers vaccines, pharmaceuticals, and vitamins for horses, piglets, and cows. The company also provides veterinary bacteriological and mycological analyses for veterinarians and animal hospitals. It serves customers in Nordic countries and the Baltic states. Intervacc AB (publ) holds an agreement with the Swedish University of Agricultural Sciences, SLU for the development of animal health vaccines. The company is based in HÃ¤gersten, Sweden.",
    "website": "http://www.intervacc.se",
    "zipcode": "129 44"
  },
  "KAN.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Kancera AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Kancera AB",
    "state": null,
    "summary": "Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567 and KAND145 which block the Fractalkine receptor CX3CR1 and thus specific parts of the immune system for treatment of hyperinflammation HDAC6 for the treatment of nerve inflammation and pain; and ROR inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.",
    "website": "http://www.kancera.com",
    "zipcode": "171 65"
  },
  "KDEV.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Karolinska Development AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Karolinska Development AB ser.B",
    "state": null,
    "summary": "Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.karolinskadevelopment.com",
    "zipcode": "17165"
  },
  "LIDDS.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "LIDDS AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIDDS AB",
    "state": null,
    "summary": "LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an antibody-based immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.",
    "website": "http://www.liddspharma.com",
    "zipcode": "754 50"
  },
  "LIPUM.ST": {
    "city": "UmeÃ¥",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Lipum AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Lipum AB",
    "state": null,
    "summary": "Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. The company was founded in 2010 and is headquartered in UmeÃ¥, Sweden.",
    "website": "http://www.lipum.se",
    "zipcode": "907 36"
  },
  "LPGO.ST": {
    "city": "UmeÃ¥",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Lipigon Pharmaceuticals AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Lipigon Pharmaceuticals AB",
    "state": null,
    "summary": "Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) was founded in 2010 and is based in UmeÃ¥, Sweden.",
    "website": "http://www.lipigon.se",
    "zipcode": "90736"
  },
  "MAGLE.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Magle Chemoswed Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Magle Chemoswed Holding AB",
    "state": null,
    "summary": "Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacture of pharmaceutical products and technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); research, development, and production of products in the areas of wound care and diagnostics, with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical device technology products in the areas of advanced wound care, surgical and diagnostics, drug delivery, which include its marketed technology products comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; and SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company is headquartered in MalmÃ¶, Sweden. Magle Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.",
    "website": "http://www.maglechemoswed.cow",
    "zipcode": "212 15"
  },
  "MVIR-B.ST": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Medivir AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Medivir AB ser. B",
    "state": null,
    "summary": "Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name; and simeprevir. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; and MIV-711, which is in phase II clinical trial for treating osteoarthritis. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.",
    "website": "http://www.medivir.com",
    "zipcode": "141 22"
  },
  "MVR.F": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Medivir AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDIVIR AB B  SK 10",
    "state": null,
    "summary": "Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name; and simeprevir. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; and MIV-711, which is in phase II clinical trial for treating osteoarthritis. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.",
    "website": "http://www.medivir.com",
    "zipcode": "141 22"
  },
  "NXTCL.ST": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "NextCell Pharma AB",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NextCell Pharma AB",
    "state": null,
    "summary": "NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases, as well as for use in kidney transplants. It also provides a service under the Cellaviva brand name, which is a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. The company has a partnership with Bonzun Health Information AB. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden.",
    "website": "http://www.nextcellpharma.com",
    "zipcode": "141 57"
  },
  "ONCO.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Oncopeptides AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Oncopeptides AB",
    "state": null,
    "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.oncopeptides.se",
    "zipcode": "111 53"
  },
  "ONCOZ.ST": {
    "city": "Bromma",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "OncoZenge AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "OncoZenge AB",
    "state": null,
    "summary": "OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).",
    "website": "http://www.oncozenge.se",
    "zipcode": "167 51"
  },
  "OND.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Oncopeptides AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ONCOPEPTIDES AB O.N.",
    "state": null,
    "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.oncopeptides.se",
    "zipcode": "111 53"
  },
  "P0F.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Egetis Therapeutics AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EGETIS THERAPEUTICS AB",
    "state": null,
    "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was founded in 2006 and is based in Stockholm, Sweden.",
    "website": "http://www.egetis.com",
    "zipcode": "114 46"
  },
  "P0F.SG": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Egetis Therapeutics AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EGETIS THERAPEUTICS AB",
    "state": null,
    "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was founded in 2006 and is based in Stockholm, Sweden.",
    "website": "http://www.egetis.com",
    "zipcode": "114 46"
  },
  "PHARM.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Pharmiva AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Pharmiva AB",
    "state": null,
    "summary": "Pharmiva AB (publ) engages in the research and development of medical products. The company develops Vernivia, an over-the-counter vaginal mousse for the treatment of bacterial vaginosis. The company is based in Lund, Sweden.",
    "website": "http://www.pharmiva.com",
    "zipcode": "22270"
  },
  "PROMO.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Promore Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Promore Pharma AB",
    "state": null,
    "summary": "Promore Pharma AB (publ), a biopharmaceutical company, develops therapeutic peptides for the bio-active wound care market in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand, which is in Phase III trial; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers and for the treatment of diabetic foot ulcers. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is based in Solna, Sweden.",
    "website": "http://www.promorepharma.com",
    "zipcode": "171 65"
  },
  "QUIA.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "QuiaPEG Pharmaceuticals Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "QuiaPEG Pharmaceuticals Holding",
    "state": null,
    "summary": "QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.",
    "website": "http://www.quiapeg.com",
    "zipcode": "171 65"
  },
  "REDW.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Redwood Pharma AB",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Redwood Pharma AB",
    "state": null,
    "summary": "Redwood Pharma AB engages in the development of ophthalmic pharmaceutical therapies for unmet market needs. The company's lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women. It uses IntelliGel, a supramolecular smart drug delivery system for development of topical formulation for ophthalmic uses, as well as for administration to the front of the eye. Redwood Pharma AB is based in Stockholm, Sweden.",
    "website": "http://www.redwoodpharma.se",
    "zipcode": "118 60"
  },
  "SIMRIS-B.ST": {
    "city": "HammenhÃ¶g",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Simris Alg AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Simris Alg AB ser. B",
    "state": null,
    "summary": "Simris Alg AB (publ) manufactures and sells dietary supplements and algae-based foods in Sweden and internationally. It offers Simris Algae Omega-3, a plant-based marine omega-3 EPA and DHA line; and a line of algae-based products, such as finest chlorella, spirulina sprinkles, boosting astaxanthin, flower power algae tea, and sun candy algae tea under the Simris Select brand. The company was founded in 2010 and is headquartered in HammenhÃ¶g, Sweden.",
    "website": "http://www.simrisalg.se",
    "zipcode": "276 50"
  },
  "SPAGO.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Spago Nanomedical AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Spago Nanomedical AB",
    "state": null,
    "summary": "Spago Nanomedical AB (publ) develops nanomaterials for cancer diagnostics and treatment. It offers SpagoPix, a cancer selective MRI contrast agent; and Tumorad, a tumor selective radiation treatment. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was founded in 2007 and is based in Lund, Sweden.",
    "website": "http://spagonanomedical.se",
    "zipcode": "223 63"
  },
  "SPRINT.ST": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Sprint Bioscience AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Sprint Bioscience AB",
    "state": null,
    "summary": "Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PIP4K2, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.",
    "website": "http://www.sprintbioscience.com",
    "zipcode": "141 57"
  },
  "STABL.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Stayble Therapeutics AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Stayble Therapeutics AB",
    "state": null,
    "summary": "Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) is based in Gothenburg, Sweden.",
    "website": "http://www.staybletherapeutics.se",
    "zipcode": "413 90"
  },
  "VICO.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Vicore Pharma Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Vicore Pharma Holding AB",
    "state": null,
    "summary": "Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), diffuse systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.vicorepharma.com",
    "zipcode": "411 05"
  },
  "XBRANE.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Xbrane Biopharma AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Xbrane Biopharma AB",
    "state": null,
    "summary": "Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.",
    "website": "http://www.xbrane.com",
    "zipcode": "171 65"
  },
  "XINT.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Xintela AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Xintela AB",
    "state": null,
    "summary": "Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing Xintela Assay for Cell Therapy (XACT), an analytical test for cell therapy. It also offers XSTEM-OA, a stem cell-based product for the treatment of osteoarthritis in humans. In addition, the company develops stem cell-based products for animals. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.",
    "website": "http://www.xintela.se",
    "zipcode": "223 81"
  },
  "XSPRAY.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Xspray Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Xspray Pharma AB",
    "state": null,
    "summary": "Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.",
    "website": "http://www.xspraypharma.com",
    "zipcode": "169 67"
  },
  "ZICC.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Ziccum AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Ziccum AB",
    "state": null,
    "summary": "Ziccum AB (publ) develops dry powder preparations of biological pharmaceuticals. The company develops and commercializes LaminarPace, a spray drying technology that dries chemicals, vaccines, biologics, and drug substances at room temperature. Its dry powder biologics includes proteins, antibodies, vaccine viruses, and other products. The company was founded in 2017 and is headquartered in Lund, Sweden.",
    "website": "http://www.ziccum.com",
    "zipcode": "223 70"
  }
}
